Common name
(3R,4R)-tetrahydrofuran-3,4-diol
IUPAC name
(3R,4R)-tetrahydrofuran-3,4-diol
SMILES
O1CC(C(C1)O)O
Common name
(3R,4R)-tetrahydrofuran-3,4-diol
IUPAC name
(3R,4R)-tetrahydrofuran-3,4-diol
SMILES
O1CC(C(C1)O)O
INCHI
InChI=1S/C4H8O3/c5-3-1-7-2-4(3)6/h3-6H,1-2H2/t3-,4-/m1/s1
FORMULA
C4H8O3
Common name
(3R,4R)-tetrahydrofuran-3,4-diol
IUPAC name
(3R,4R)-tetrahydrofuran-3,4-diol
Molecular weight
104.105
clogP
-0.109
clogS
0.954
Frequency
0.0024
HBond Acceptor
3
HBond Donor
2
Total PolarSurface Area
49.69
Number of Rings
1
Rotatable Bond
0
| Drug ID | Common name | Structure CAS | Compound class | Therapeutic area |
|---|---|---|---|---|
| FDBD00083 | Vidarabine |
|
Antiviral Agents; Antimetabolites; Ophthalmologicals; Sensory Organs; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors; Antiinfectives; | For treatment of chickenpox - varicella, herpes zoster and herpes simplex. |
| FDBD00503 | Inulin |
|
Diagnostic Agents; Tests for Renal Function and Ureteral Injuries; | Historically used in an important medical test of renal function, specifically a measure of glomerular filtration rate. Sometimes used to help relieve symptoms of diabetes mellitus - a condition characterised by hyperglycemia and/or hyperinsulinemia. |
| FDBD00841 | Cytarabine |
|
Antineoplastic Agents; Antiviral Agents; Immunosuppressive Agents; Antimetabolites; Antimetabolites, Antineoplastic; Antineoplastic and Immunomodulating Agents; Pyrimidine Analogues; CYP3A4 Inhibitors; | For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. |
| FDBD00924 | Fludarabine |
|
Antineoplastic Agents; Immunosuppressive Agents; Antimetabolites; Antimetabolites, Antineoplastic; Purine analogues; Antineoplastic and Immunomodulating Agents; | For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen. |
| FDBD01113 | Nelarabine |
|
Antineoplastic Agents; Immunosuppressive Agents; Antimetabolites; Purine analogues; Antineoplastic and Immunomodulating Agents; | For the treatment of pediatric and adult patients with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. |
| FDBD01294 | Flavin adenine dinucleotide |
|
; | Used to treat eye diseases caused by vitamin B2 deficiency, such as keratitis and blepharitis. |
| FDBD01713 | Sucroferric Oxyhydroxide |
|
Iron Preparations; Blood and Blood Forming Organs; Antianemic Preparations; Drugs for Treatment of Hyperkalemia and Hyperphosphatemia; Drugs for Treatment of Hyperkalemia and Hypophosphatemia; Iron Trivalent, Oral Preparations; |
7 ,
1
| FRAGNAME | PDBID | SIMILIRITY | XSCORE | SMILE | HAC |
|---|---|---|---|---|---|
| 1hp0_ligand_frag_1.mol2 | 1hp0 | 1 | -6.49 | C1[C@H]([C@H](CO1)O)O | 7 |
| 1ctu_ligand_frag_1.mol2 | 1ctu | 1 | -6.27 | C1OC[C@H]([C@H]1O)O | 7 |
| 1af2_ligand_frag_1.mol2 | 1af2 | 1 | -6.23 | C1OC[C@@H]([C@@H]1O)O | 7 |
| 2wr8_ligand_frag_5.mol2 | 2wr8 | 1 | -6.21 | C1OC[C@@H]([C@@H]1O)O | 7 |
| 4kxl_ligand_frag_3.mol2 | 4kxl | 1 | -6.21 | C1OC[C@H]([C@H]1O)O | 7 |
| 4kxm_ligand_frag_3.mol2 | 4kxm | 1 | -6.20 | C1OC[C@@H]([C@@H]1O)O | 7 |
| 1ctt_ligand_frag_1.mol2 | 1ctt | 1 | -6.19 | C1[C@@H]([C@@H](CO1)O)O | 7 |
| 2b1i_ligand_frag_1.mol2 | 2b1i | 1 | -6.19 | C1OC[C@H]([C@H]1O)O | 7 |
| 2xaf_ligand_frag_3.mol2 | 2xaf | 1 | -6.17 | C1OC[C@@H]([C@@H]1O)O | 7 |
| 1m9n_ligand_frag_1.mol2 | 1m9n | 1 | -6.16 | C1OC[C@@H]([C@@H]1O)O | 7 |
744 ,
75
